Shimada H, Miki T, Kyogoku I, Kawagishi T, Inaba M, Okuno Y, Nishizawa Y, Morii H
Department of Geriatrics and Neurology, Osaka City University Medical School, Japan.
No To Shinkei. 1998 Sep;50(9):817-20.
The effects of the aldose reductase inhibitor epalrestat (150 mg/day) on electrophysiological function were examined in 22 NIDDM patients with diabetic polyneuropathy for 6 months. Although no significant differences were observed in sensory (the sural nerve) or motor (the posterior tibial nerve) conduction velocities and amplitude, only F wave conduction velocities were significantly improved at 3 and 6 months after the treatment. There were no significant changes in CV-RR, vibration threshold and laboratory data. No serious side effects were observed during the therapeutic trial. This study suggests F wave is appropriate for the assessment of diabetic neuropathy and for therapeutic trials.
在22例患有糖尿病性多发性神经病变的非胰岛素依赖型糖尿病（NIDDM）患者中，研究了醛糖还原酶抑制剂依帕司他（150毫克/天）对电生理功能的影响，为期6个月。尽管在感觉神经（腓肠神经）或运动神经（胫后神经）的传导速度和波幅方面未观察到显著差异，但仅在治疗后3个月和6个月时，F波传导速度有显著改善。CV-RR、振动阈值和实验室数据均无显著变化。在治疗试验期间未观察到严重的副作用。本研究表明，F波适用于评估糖尿病神经病变以及治疗试验。
